Study of CM313 (SC) Injection in Patients With Primary Immune Thrombocytopenia (ITP)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.
Epistemonikos ID: 0625daf13f4a1082cd555266bc813c1f8488a704
First added on: Oct 01, 2024